HIV-1 uncoating by release of viral cDNA from capsid-like structures in the nucleus of infected cells.


Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
27 04 2021
Historique:
received: 10 11 2020
accepted: 21 04 2021
pubmed: 28 4 2021
medline: 28 10 2021
entrez: 27 4 2021
Statut: epublish

Résumé

HIV-1 replication commences inside the cone-shaped viral capsid, but timing, localization, and mechanism of uncoating are under debate. We adapted a strategy to visualize individual reverse-transcribed HIV-1 cDNA molecules and their association with viral and cellular proteins using fluorescence and correlative-light-and-electron-microscopy (CLEM). We specifically detected HIV-1 cDNA inside nuclei, but not in the cytoplasm. Nuclear cDNA initially co-localized with a fluorescent integrase fusion (IN-FP) and the viral CA (capsid) protein, but cDNA-punctae separated from IN-FP/CA over time. This phenotype was conserved in primary HIV-1 target cells, with nuclear HIV-1 complexes exhibiting strong CA-signals in all cell types. CLEM revealed cone-shaped HIV-1 capsid-like structures and apparently broken capsid-remnants at the position of IN-FP signals and elongated chromatin-like structures in the position of viral cDNA punctae lacking IN-FP. Our data argue for nuclear uncoating by physical disruption rather than cooperative disassembly of the CA-lattice, followed by physical separation from the pre-integration complex. When viruses infect human cells, they hijack the cell’s machinery to produce the proteins they need to replicate. Retroviruses like HIV-1 do this by entering the nucleus and inserting their genetic information into the genome of the infected cell. This requires HIV-1 to convert its genetic material into DNA, which is then released from the protective shell surrounding it (known as the capsid) via a process called uncoating. The nucleus is enclosed within an envelope containing pores that molecules up to a certain size can pass through. Until recently these pores were thought to be smaller than the viral capsid, which led scientists to believe that the HIV-1 genome must shed this coat before penetrating the nucleus. However, recent studies have found evidence for HIV-1 capsid proteins and capsid structures inside the nucleus of some infected cells. This suggests that the capsid may not be removed before nuclear entry or that it may even play a role in helping the virus get inside the nucleus. To investigate this further, Müller et al. attached fluorescent labels to the newly made DNA of HIV-1 and some viral and cellular proteins. Powerful microscopy tools were then used to monitor the uncoating process in various cells that had been infected with the virus. Müller et al. found large amounts of capsid protein inside the nuclei of all the infected cells studied. During the earlier stages of infection, the capsid proteins were mostly associated with viral DNA and the capsid structure appeared largely intact. At later time points, the capsid structure had been broken down and the viral DNA molecules were gradually separating themselves from these remnants. These findings suggest that the HIV-1 capsid helps the virus get inside the nucleus and may protect its genetic material during conversion into DNA until right before integration into the cell’s genome. Further experiments studying this process could lead to new therapeutic approaches that target the capsid as a way to prevent or treat HIV-1.

Autres résumés

Type: plain-language-summary (eng)
When viruses infect human cells, they hijack the cell’s machinery to produce the proteins they need to replicate. Retroviruses like HIV-1 do this by entering the nucleus and inserting their genetic information into the genome of the infected cell. This requires HIV-1 to convert its genetic material into DNA, which is then released from the protective shell surrounding it (known as the capsid) via a process called uncoating. The nucleus is enclosed within an envelope containing pores that molecules up to a certain size can pass through. Until recently these pores were thought to be smaller than the viral capsid, which led scientists to believe that the HIV-1 genome must shed this coat before penetrating the nucleus. However, recent studies have found evidence for HIV-1 capsid proteins and capsid structures inside the nucleus of some infected cells. This suggests that the capsid may not be removed before nuclear entry or that it may even play a role in helping the virus get inside the nucleus. To investigate this further, Müller et al. attached fluorescent labels to the newly made DNA of HIV-1 and some viral and cellular proteins. Powerful microscopy tools were then used to monitor the uncoating process in various cells that had been infected with the virus. Müller et al. found large amounts of capsid protein inside the nuclei of all the infected cells studied. During the earlier stages of infection, the capsid proteins were mostly associated with viral DNA and the capsid structure appeared largely intact. At later time points, the capsid structure had been broken down and the viral DNA molecules were gradually separating themselves from these remnants. These findings suggest that the HIV-1 capsid helps the virus get inside the nucleus and may protect its genetic material during conversion into DNA until right before integration into the cell’s genome. Further experiments studying this process could lead to new therapeutic approaches that target the capsid as a way to prevent or treat HIV-1.

Identifiants

pubmed: 33904396
doi: 10.7554/eLife.64776
pii: 64776
pmc: PMC8169111
doi:
pii:

Substances chimiques

Capsid Proteins 0
DNA, Viral 0
reverse transcriptase, Human immunodeficiency virus 1 EC 2.7.7.-
HIV Reverse Transcriptase EC 2.7.7.49

Types de publication

Journal Article Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2021, Müller et al.

Déclaration de conflit d'intérêts

TM, VZ, KP, SS, MS, BL, VL, ML, BM, HK No competing interests declared

Références

J Virol. 2017 Apr 13;91(9):
pubmed: 28250118
J Struct Biol. 2017 Feb;197(2):83-93
pubmed: 27368127
Nat Biotechnol. 2003 Jan;21(1):86-9
pubmed: 12469133
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Viruses. 2018 Nov 10;10(11):
pubmed: 30423802
Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23735-23742
pubmed: 31685613
J Virol. 2020 May 18;94(11):
pubmed: 32238582
Nat Rev Microbiol. 2015 Aug;13(8):471-83
pubmed: 26179359
Proc Natl Acad Sci U S A. 2017 Aug 22;114(34):E7169-E7178
pubmed: 28784755
Retrovirology. 2013 Jul 09;10:70
pubmed: 23835323
Cell Rep. 2015 Nov 24;13(8):1717-31
pubmed: 26586435
PLoS Pathog. 2013;9(10):e1003693
pubmed: 24130490
Virol Sin. 2019 Apr;34(2):119-134
pubmed: 31028522
EMBO J. 2003 Apr 1;22(7):1707-15
pubmed: 12660176
PLoS Genet. 2014 Mar 13;10(3):e1004187
pubmed: 24625580
Nature. 2015 Oct 1;526(7571):140-143
pubmed: 26416747
J Virol. 2015 Dec 09;90(4):2064-76
pubmed: 26656698
J Virol. 2006 Feb;80(4):1939-48
pubmed: 16439549
Nat Methods. 2018 Dec;15(12):1090-1097
pubmed: 30478326
Cell Host Microbe. 2018 Apr 11;23(4):536-548.e6
pubmed: 29649444
Science. 2020 Oct 9;370(6513):
pubmed: 33033190
PLoS Pathog. 2014 Oct 30;10(10):e1004459
pubmed: 25356722
Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9975-80
pubmed: 21628558
J Cell Biol. 2011 Jan 10;192(1):111-9
pubmed: 21200030
Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905
pubmed: 12019106
Elife. 2014 Dec 17;3:e04114
pubmed: 25517934
Cell. 2021 Feb 18;184(4):1032-1046.e18
pubmed: 33571428
mBio. 2019 Nov 5;10(6):
pubmed: 31690677
J Virol. 2017 May 26;91(12):
pubmed: 28381579
Retrovirology. 2016 Apr 23;13:28
pubmed: 27107820
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E1054-63
pubmed: 26858452
Nat Commun. 2020 Jul 14;11(1):3505
pubmed: 32665593
Sci Adv. 2020 Sep 23;6(39):
pubmed: 32967822
PLoS Pathog. 2017 Aug 21;13(8):e1006570
pubmed: 28827840
Proc Natl Acad Sci U S A. 1989 Mar;86(5):1624-8
pubmed: 2922401
EMBO J. 2007 Jun 20;26(12):3025-37
pubmed: 17557080
J Virol. 2015 May;89(10):5350-61
pubmed: 25741002
Biophys J. 2017 Oct 3;113(7):1383-1394
pubmed: 28978433
Proc Natl Acad Sci U S A. 2020 Mar 10;117(10):5486-5493
pubmed: 32094182
Cell Rep. 2020 Sep 29;32(13):108201
pubmed: 32997983
J Virol Methods. 2009 Mar;156(1-2):1-7
pubmed: 19022294
J Virol. 2018 Aug 29;92(18):
pubmed: 29997215
Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18625-30
pubmed: 25518861
Cancer Res. 1984 Dec;44(12 Pt 1):5657-60
pubmed: 6437672
Nat Microbiol. 2020 Sep;5(9):1088-1095
pubmed: 32483230
Virology. 2013 May 25;440(1):8-18
pubmed: 23523133
Nat Rev Microbiol. 2017 Feb;15(2):69-82
pubmed: 27941817
Nat Methods. 2017 Jan 31;14(2):102-103
pubmed: 28139674
J Struct Biol. 2005 Oct;152(1):36-51
pubmed: 16182563
Nature. 2013 Nov 21;503(7476):402-405
pubmed: 24196705
EMBO J. 2020 Oct 15;39(20):e103958
pubmed: 32852081
Nat Methods. 2017 Jan;14(1):53-56
pubmed: 27869816
Prog Mol Biol Transl Sci. 2015;129:285-326
pubmed: 25595808
Nat Commun. 2015 Mar 06;6:6483
pubmed: 25744187
Curr Opin Virol. 2018 Dec;33:1-6
pubmed: 30015082
Nat Struct Mol Biol. 2004 Jul;11(7):672-5
pubmed: 15208690
J Virol. 2018 Aug 29;92(18):
pubmed: 29950406
EMBO J. 2020 May 4;39(9):e102209
pubmed: 32157726
Retrovirology. 2011 Jun 22;8:49
pubmed: 21696578
Nature. 2014 Jan 23;505(7484):509-14
pubmed: 24356306
Retrovirology. 2016 Aug 22;13(1):58
pubmed: 27549239
Science. 2016 Dec 16;354(6318):1434-1437
pubmed: 27980210
FEBS Lett. 2004 Apr 9;563(1-3):113-8
pubmed: 15063733
J Virol. 1995 Jun;69(6):3938-44
pubmed: 7745750
PLoS Pathog. 2011 Aug;7(8):e1002194
pubmed: 21901095
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Retrovirology. 2012 Jul 25;9:60
pubmed: 22830600
PLoS One. 2008 Jun 11;3(6):e2413
pubmed: 18545681
Nature. 2015 May 14;521(7551):227-31
pubmed: 25731161
EMBO J. 2021 Jan 4;40(1):e105247
pubmed: 33270250
Nat Commun. 2017 Dec 1;8(1):1882
pubmed: 29192235
Science. 2014 Jan 24;343(6169):428-32
pubmed: 24356113
EMBO J. 2001 Jun 15;20(12):3272-81
pubmed: 11406603
Cell Host Microbe. 2018 Sep 12;24(3):392-404.e8
pubmed: 30173955
Molecules. 2019 Jan 29;24(3):
pubmed: 30700005
Nat Methods. 2012 Jun 28;9(7):690-6
pubmed: 22743774
J Struct Biol. 1996 Jan-Feb;116(1):71-6
pubmed: 8742726
J Virol. 2011 Jul;85(13):6263-74
pubmed: 21507971
Nat Rev Microbiol. 2007 Mar;5(3):187-96
pubmed: 17304248
Elife. 2019 Jan 23;8:
pubmed: 30672737
Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8392-6
pubmed: 7690960

Auteurs

Thorsten G Müller (TG)

Department of Infectious Diseases Virology, University Hospital Heidelberg, Heidelberg, Germany.

Vojtech Zila (V)

Department of Infectious Diseases Virology, University Hospital Heidelberg, Heidelberg, Germany.

Kyra Peters (K)

Department of Infectious Diseases Virology, University Hospital Heidelberg, Heidelberg, Germany.

Sandra Schifferdecker (S)

Department of Infectious Diseases Virology, University Hospital Heidelberg, Heidelberg, Germany.

Mia Stanic (M)

Department of Infectious Diseases Integrative Virology, University Hospital Heidelberg, Heidelberg, Germany.

Bojana Lucic (B)

Department of Infectious Diseases Integrative Virology, University Hospital Heidelberg, Heidelberg, Germany.

Vibor Laketa (V)

Department of Infectious Diseases Virology, University Hospital Heidelberg, Heidelberg, Germany.
German Center for Infection Research, partner site Heidelberg, Heidelberg, Germany.

Marina Lusic (M)

Department of Infectious Diseases Integrative Virology, University Hospital Heidelberg, Heidelberg, Germany.
German Center for Infection Research, partner site Heidelberg, Heidelberg, Germany.

Barbara Müller (B)

Department of Infectious Diseases Virology, University Hospital Heidelberg, Heidelberg, Germany.

Hans-Georg Kräusslich (HG)

Department of Infectious Diseases Virology, University Hospital Heidelberg, Heidelberg, Germany.
German Center for Infection Research, partner site Heidelberg, Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH